Clinical Trial Update: Akt Inhibitor MK2206 in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 trial of MK2206, an Akt inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma has completed with results posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• MK2206 (MK2206)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Diffuse Large B Cell Lymphoma | Phase 2 | Status: COMPLETED | Results posted: 2017-04-07